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background: To report clinical outcomes and late toxicities of a 2-week hypofractionated post-operative loco-regional radio-
therapy in patients with breast cancer.
Materials and methods: This trial was approved by the Institutional ethics committee and registered with gov, 
no. NcT02460744. Between June 2013 and October 2014, 50 patients with breast cancer, post mastectomy or breast conserv-
ing surgery (Bcs) were included in this study, of whom 10 had Bcs. patients were planned on a 2-dimentional (2D) simulator 
with 2 tangential fields and an incident supraclavicular field. radiotherapy dose was 34 Gy/10#/2 weeks and a sequential 
boost of 10 Gy/5#/1 wk in Bcs patients. The primary endpoint was the rate of acute skin toxicities previously reported. here, 
we report the secondary end points of late toxicities, cosmesis, local recurrence, disease-free survival (DFs) and overall survival 
(Os). Late skin toxicities were recorded according to the radiotherapy and Oncology Group (rTOG) scoring criteria. cosmetic 
outcomes were assessed using the harvard/National surgical adjuvant Breast and Bowel project (NsaBp)/rTOG breast cos-
mesis and the Late effects Normal Tissue/subjective Objective Management analytic (LeNT/sOMa) scales for the breast and 
chest wall, respectively. Kaplan-Meier estimates of DFs and Os were calculated, and 5-year DFs and Os rates (with approximate 
95% cIs) were estimated.
results: Late grade ≥ 2 chest wall induration, hypopigmentation and subcutaneous fibrosis were seen in 3 (6%), 3 (6%) and 
1 (2%) patients, respectively. chest wall cosmesis was excellent/good in 34 (72%) and fair/bad in 13 (28%) patients. In Bcs 
patients, grade 2 skin induration, subcutaneous fibrosis and edema was observed in 1 patient (11%) each. cosmesis was excel-
lent/good in 7 (78%) and fair/bad in 2 (22%) patients. Late grade ≥ 2 arm edema, pain and shoulder stiffness were reported 
by 1 (2%), 2 (4%) and 2 (4%) patients, respectively. No local recurrences were observed. Five patients developed distant me-
tastases (10%). seven patients died (14%). The 5-year DFs and Os rate was 90% (95% cI: 77–96%) and 88% (95% cI: 75–94%), 
respectively.
conclusion: hypofractionated radiotherapy in 2 weeks in patients with breast cancer was associated with minimal late toxic-
ity, good cosmetic outcome and excellent local control. This trial may be of relevance for developing countries where resources 
are limited.  
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Introduction
Radiotherapy is an essential component of breast 
cancer management [1]. Hypofractionation is gain-
ing momentum in breast cancer [2–4]. Studies are 
going on to reduce total treatment duration by de-
livering a larger dose per fraction in these patients. 
In spite of continuous research, the limit for hypo-
fractionation is not yet reached. Taking a step in 
this direction, we have previously reported feasibil-
ity and early toxicity results from a phase 2 study of 
2-week post-operative loco-regional radiotherapy 
for patients with breast cancer [5]. Hypofraction-
ated radiation therapy within 2 weeks appeared to 
be feasible and was associated with an acute toxicity 
profile that was similar to what has been reported 
with a 3-week treatment. Preliminary estimates of 
3-year disease-free survival (DFS) and overall sur-
vival (OS) rates were 94% and 96%, respectively, 
after a median follow-up of 39 months.
In this manuscript, we report results for late skin 
toxicities, updated 5-year late toxicity rates, and 
clinical outcomes after a median follow-up of 60 
months.
Materials and methods
This phase 2 trial was approved by the Institu-
tional Ethics Committee and registered with Clini-
calTrials.gov, no. NCT02460744. Patient and tumor 
characteristics, as well as details of the treatment 
regimen, have been previously described [1]. Brief-
ly, between June 2013 and October 2014, 50 pa-
tients with breast cancer, post mastectomy or after 
breast conserving surgery (BCS) were included in 
this phase 2 study, of whom 10 had BCS. Inclusion 
criteria were; age ≥ 18 years, female or male patients 
with invasive carcinoma of the breast, BCS or mas-
tectomy, ≥ 10 axillary lymph nodes dissected, com-
plete microscopic excision of primary tumour, T1-4 
pN0-3 M0 disease, neoadjuvant or adjuvant chemo-
therapy, written informed consent and able to com-
ply with follow up. None of the patients received 
implants or reconstruction. Exclusion criteria were; 
past history of malignancy, except (i) basal cell skin 
cancer and CIN cervix uteri or (ii) non-breast ma-
lignancy allowed if treated with curative intent and 
at least 5-year disease free and contralateral breast 
cancer, including ductal carcinoma in-situ (DCIS), 
irrespective of date of diagnosis.
radiotherapy
Patients were planned on 2-dimensional (2D) 
fluoroscopic conventional simulator in a supine 
position on a breast board with ipsilateral arm ab-
ducted to 90º. Treatment was done with two tan-
gential opposing fields to the breast/chest wall and 
a single incident field to the supraclavicular fossa. 
Field marking for the breast/chest wall included the 
midline, medially; the midaxillary fold, laterally, 
the 2nd intercostal space, cranially, and 1cm below 
the opposite inframammary fold, caudally. For the 
supraclavicular field (SCF), the caudal border was 
the cranial border of breast/chest wall field, crani-
ally, the thyroid notch, medially, along the medial 
border of the sternocleidomastoid muscle and, lat-
erally, the insertion of deltoid. There was no gap 
between the tangential and SCF borders. 
Central lung distance (CLD) was kept between 
1–2.5 cm. Radiotherapy dose delivered was 34 
Gy/10#/2 weeks prescribed at mid separation. SCF 
dose was prescribed at dmax on cobalt or 6 MV 
linac. Internal mammary nodes were not treated 
in this study. No cardiac shielding was done. BCS 
patients were treated on 6MV linac and a 300 wedge 
was also used. A boost of 10Gy/5#/1wk was given 
to cases with BCS with photons or electrons. Boost 
was planned with digital reconstructed radiographs 
on computerized tomography (CT). 
Mastectomy patients were treated on cobalt ma-
chine with a breast cone, if separation was > 20 cm 
then they were also treated on linac. Chest wall 
bolus was used for 50% of treatment days (for 5 
fractions).
Dosimetry
Dosimetry was done in 20 patients with left 
breast cancer. Patients were planned on a 2D simu-
lator on a breast board. Field borders were set and 
CLD was calculated. Field borders were marked. 
After that, patients were taken to a CT-simulator 
for 3-dimensional (3D) treatment planning. The 
patients were positioned supine on the same breast 
board with the same parameters in the same posi-
tion. Lead wires were placed on the field borders 
and 100 ml of intravenous contrast was given. CT 
axial cuts were taken from the level of the larynx 
to the upper abdomen, including both lungs with 
a scan thickness and index of 3 mm. CT images 
were transferred to the treatment planning sys-
tem (TPS). The chest wall, heart, bilateral lungs, 
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left anterior descending coronary artery (LAD) 
and opposite breast were contoured. The treat-
ment parameters, patients and organ at risk out-
lines were exported to TPS. 3D planning was used 
to reconstruct 2D radiotherapy target volume for 
treating the chest and loco regional lymph nodes. 
Plans were made using standard tangential fields. 
Heart, bilateral lungs, LAD artery and opposite 
breast dose volume histograms were generated. 
From these, mean doses to the heart, LAD, proxi-
mal LAD, distal LAD, bilateral lung and opposite 
breast, V5 of the right lung, V5, V10 and V20 of 
the left lung and V2 of the opposite breast were 
calculated.
assessments
Patients were examined by radiation oncologists 
every 3 months for the first year, every 6 months till 
5 years for tumour recurrence and late toxicities. 
BCS cosmetic outcomes were assessed by a clini-
cian using the Harvard/National Surgical Adjuvant 
Breast and Bowel Project (NSABP)/Radiotherapy 
and Oncology Group (RTOG) breast cosmesis 
grading scale before treatment and then on regular 
follow up. Chest wall cosmesis and late skin toxici-
ties were reported as per RTOG radiation morbid-
ity scoring criteria [1]. Any symptoms for pulmo-
nary fibrosis, rib fractures and cardiac problems 
were also noted.
Outcomes
The primary endpoint was the rate of acute skin 
toxicities which has been previously published. 
Acute grade 2 and 3 skin toxicity was seen in 16 
(32%) and 1 (2%) patients, respectively [1]. Here, 
we report results for the secondary endpoint of 
physician reported late toxicities and updated re-
sults for the secondary endpoints of cosmetic out-
come, local recurrence, DFS and OS. Late skin tox-
icities were defined as any toxicity occurring after 
6 months of radiotherapy. DFS was defined as time 
from treatment to recurrence or metastasis. OS was 
defined from the date of diagnosis till death due to 
breast cancer or last follow up date.
statistical analyses
The primary objective was to obtain estimates 
of rates of acute toxicities and cosmetic outcomes 
that could be used to design a subsequent phase 3 
comparative study. The present study included 50 
patients. A sample size of 50 patients would pro-
vide a 95% confidence interval (CI) that would be 
less than ± 10% of any estimated rate. Our BCS rat 
is 25–30% of all patients, so 10 patients with BCS 
were included in this study, but the numbers are in-
adequate to separately analyze and distinguish BCS 
from mastectomy patients. The primary endpoint 
was the rate of acute skin toxicities. Secondary 
endpoints included cosmetic outcome, late toxicity, 
local recurrence, disease-free survival (DFS) and 
overall survival (OS). For cosmesis, the results were 
dichotomized as the proportion of patients with an 
excellent or good result versus the proportion with 
fair or poor result. Length of follow-up was calcu-
lated as the time from recruitment until the time of 
the first event or last follow-up assessment, which-
ever occurred first. Kaplan-Meier estimates of DFS 
and OS were calculated, and 5-year relapse and 
mortality rates, (with approximate 95% CIs) were 
estimated. All statistical analyses were performed 
using SPSS (Statistical Package for the Social Sci-
ences) v.16.0.
results
Mean age was 51 ± 12 years. Left-sided tumors 
were in 25 (50%) patients. Total mastectomy with 
axillary clearance (TMAC) was done in 40 (80%) 
and BCS in 10 (20%) patients (Tab. 1). Histopa-
thology was luminal A, luminal B, Her2/neu rich 
and TNBC in 12 (24%), 8 (16%), 10 (20%) and 20 
(40%) patients, respectively. Regional nodal irra-
diation was done in all patients. Median tangential 
chest wall/breast separation was 18 cm (range 15 to 
25cm). CLD was 2 cm (range 1.4 to 2.8 cm).
Median follow-up was 60 months (range 14–100 
months). Late toxicities were assessed in 47 of the 
50 patients (Tab. 2). Three patients died, 2 because 
of infection and 1 due to metastatic disease before 
late toxicity assessment. Physician reported late 
grade ≥ 2 chest wall induration, hypopigmentation 
and subcutaneous fibrosis at 5 years were seen in 
3 (6%), 3 (6%) and 1 (2%) patients, respectively. 
Late toxicities did not deteriorate over the years. 
Chest wall edema subsided with time. It was seen 
in 2 (4%) patients at 3 years. At 5 years, chest wall 
edema was not observed in any patient.
Chest wall cosmesis was excellent/good in 34 
patients (72%, 95% CI: 57–84%) and fair/bad in 13 
patients (28%, 95% CI: 16–43). Only 1 patient (2%) 
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had grade 3 late toxicity in the form of induration. 
There was no detrimental effect on chest wall cos-
mesis over the years. 
Nine of the 10 patients with BCS were assessed 
for late toxicities; one died due to metastatic dis-
ease. Grade 2 skin induration, subcutaneous fibro-
sis and edema were observed in 1 patient (11%) 
each. Cosmesis was excellent/good in 7 patients 
(78%, 95% CI: 40–97%) and fair/bad in 2 patients 
(22%, 95% CI 3–60%). Cosmesis was also stable 
over time. There was no grade 3 late breast toxicity. 
There was no telangiectasia.
Arm and shoulder function were assessed in 
46 patients (Tab. 3). Four patients could not be 
assessed for arm and shoulder function. Late 
grade ≥ 2 arm edema, pain and shoulder stiffness 
were reported by 1 patient (2%, 95% CI: 0–12%), 
2  patients (4%, 95% CI: 1–15%) and 2 patients 
(4%, 95% CI: 1–15%), respectively. Arm and shoul-
der functions did not deteriorate with time. There 
was no brachial plexopathy, rib fracture, pulmonary 
or cardiac toxicity. No second cancers have been 
reported.
No local recurrences were observed. Five pa-
tients developed distant metastases (10%, 95% CI: 
1.2–16.5%): 2 lung, 1 bone, 1 liver and 1 ascites. 
Among these, luminal A, Her2/neu rich and TNBC 
were found in 1 (2%), 2 (4%) and 2 (4%) patients, 
respectively. Seven patients died (14%, 95% CI: 
5–28%); 5 due to metastases (10%, 95% CI 3–24%) 
and 2 because of infection (4%, 95% CI: 0–13%). 
The 5-year DFS rate was 90% (95% CI: 77–96%) 
(Fig. 1) and the 5-year OS rate was 88% (95% CI: 
75–94%) (Fig. 2).
Estimated Dmax was up to 120% of the prescribed 
dose and the prescribed dose coverage of the target 
was 92–95% of the prescribed dose. Mean doses to 
the heart, LAD, proximal LAD and distal LAD were 
3.07 ± 1.25 Gy (EQD2 = 2.03 Gy), 12.92 ± 6.46 Gy 
(EQD2 = 11.09 Gy), 3.60 ± 3.81 Gy (EQD2 = 2.42 
Gy) and 21.14 ± 9.77 Gy (EQD2 = 21.62 Gy), re-
spectively (Fig. 3). Mean doses to the left lung, V5, 
V10 and V20 were 8.24±3.50 Gy (EQD2 = 6.30 Gy), 
28.40 ± 13.56%, 24.59 ± 10.61% and 20.00 ± 9.15%, 
respectively (Fig. 4). Mean dose to opposite breast 
was 0.43 ± 0.31 Gy (EQD2 = 0.26 Gy). Brachial 
plexus was contoured in 15 patients. Brachi-
al plexus Dmean and Dmax were 29.54 ± 11.25 
Gy (EQD2 = 35.18 Gy) and 37.63 ± 16.63 Gy 
(EQD2 = 50.90 Gy), respectively (Fig. 5). Dmax to 
table 1. patient and tumor characteristics
Characteristic n(%) 95% CI
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the brachial plexus was consistent between 35.30 Gy 
(EQD2 = 46.10 Gy) to 39.25 Gy (EQD2 = 54.36 Gy). 
Discussion
In this phase 2 study of 2-week hypofraction-
ation in patients with breast cancer with a 2D tech-
nique, late toxicities were acceptable, cosmesis was 
good and local control was excellent. Overall ad-
verse events were low. Late grade 3 skin toxicity was 
observed only in 1 (2%) patient in the form of skin 
induration of the chest wall.
The objective of loco-regional irradiation in 
breast cancer is to reduce loco-regional recurrence 
table 3. arm and shoulder function
Toxicity
3 year (n = 48) 5 year (n = 46)
n(%) 95% CI n(%) 95% CI
Arm edema
rTOG Grade 0 43 90) 77–97 41(89) 76–96
rTOG Grade 1 4 (8) 2–20 4(9) 2–21
rTOG Grade 2 0 (0) 0–7 0(0) 0–8
rTOG Grade 3 1 (2) 0–11 1(2) 0–12
Arm pain
rTOG Grade 0 46 (96) 86–99 44(96) 85–99
rTOG Grade 1 2 (4) 1–14 2(4) 1–15
shoulder stiffness
rTOG Grade 0 47 (98) 89–100 44(96) 85–99
rTOG Grade 2 1 (2) 0–11 2(4) 1–15
rTOG — radiation Therapy Oncology Group  cI — confidence interval; cI — confidence interval
Table 2. Late toxicities
Late toxicity
All patients Patients with BCS
3 year (n = 48) 5 year (n = 47) 3 year (n = 10) 5 year (n = 9)
n (%) 95% CI n (%) 95% CI n (%) 95% CI n (%) 95% CI
skin induration
rTOG Grade 0 28 (58) 43–72 28 (60) 44–74 4 (40) 12–74 4 (44) 14–79
rTOG Grade 1 17 (35) 22–51 16 (34) 21–49 4 (40) 12–74 4 (44) 14–79
rTOG Grade 2 2 (4) 1–14 2 (4) 1–15 2 (20) 3–56 1 (11) 0–48
rTOG Grade 3 1 (2) 0–11 1 (2) 0–11 0 ( 0) 0–31 0 (0) 0–34
Hypopigmentation
rTOG Grade 0 46 (96) 86–99 44 (94) 82–99 10 (100) 69–100 9 (100) 66–100
rTOG Grade 2 2 (4) 1–14 3 (6) 1–18 0 (0) 0–31 0 (0) 0–34
subcutaneous fibrosis
rTOG Grade 0 47 ( 98) 89–100 46 (98) 89–100 9 (90) 56–100 8 (89) 52–100
rTOG Grade 2 1 (2) 0–11 1 (2) 0–11 1 (10) 0–44 1 (11) 0–48
chest wall edema
rTOG Grade 0 46 (96) 86–99 47 (100) 92–100 8 (80) 44–97 8 (89) 52–100
rTOG Grade 2 2 (4) 1–14 0 (0) 0–8 2 (20) 3–56 1 (11) 0–48
cosmesis
excellent/Good 34 (71) 56–83 34 (72) 57–84 8 (80) 44–97 7 (78) 40–97
Fair/poor 14 (29) 17–44 13 (28) 16–43 2 (20) 3–56 2 (22) 3–60
Bcs — breast conserving surgery; rTOG — radiation Therapy Oncology Group  cI — confidence interval
Reports of Practical Oncology and Radiotherapy 2021, vol. 26, no. 4
https://journals.viamedica.pl/rpor508














1 2   3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Figure 3. Mean doses to organs at risk (dose along Y-axis and patients along X-axis). LaD — left anterior descending coronary 
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Figure 4. Left lung mean dose, V10 and V20 (dose along Y-axis and patients along X-axis). MLD — mean lung dose; 
V10 — volume receiving 10 Gy; V20 — volume receiving 20 Gy
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with minimal toxicity and good cosmetic outcome 
[2]. With this 2 week schedule we could achieve all 
these objectives. Even after randomised trials from 
Canada [5] and the UK [3, 4, 7], optimal sched-
ule with hypofractionation for post-operative breast 
cancer radiotherapy has not been defined yet. The 
START trials have concluded it to be 40 Gy in 15 
fractions over 3 weeks for patients with early breast 
cancer. Studies are ongoing to further reduce the 
total dose as well as duration of treatment to 2 weeks 
or 1 week in early breast cancer. All this is possible 
because in the breast α/β of the tumor is similar to 
the α/β of the normal tissue. α/β for the local recur-
rence is 3.5 Gy and 3.1 Gy for the adverse effect [3, 
4]. So, a high dose per fraction would be more ef-
fective on the tumor without much adverse effect on 
the normal breast tissue. In the present study, all late 
effects were within 2–6%. These are well within the 
range reported in the randomized trials [3–7]. The 
START A trial reported that 38.2% of the breasts 
were indurated after hypofractionation as compared 
to 42.3% with conventional fractionation [3]. In our 
study, grade 2 breast induration was observed in 
only 1 (11%) patient (Fig. 6). There was no grade 
3 induration. Our results are also comparable to 
those reported by Wang et al. [8]. The RMH/GOC 
study reported that any difference in the breast ap-
pearance was 39.6%, 30.3% and 45.1% with 50 Gy 
in conventional fractionation, 39 Gy and 42.9 Gy in 
13 fractions, respectively [7]. In the START trials, 
breast appearance change was 42.6% and 44.6% with 
conventional and hypofractionation, respectively. In 
our study, in patients with BCS, adverse effect on the 
breast was observed only in 2 (22%) patients.
A Canadian study reported similar outcomes 
with hypofractionation and conventional fraction-
ation [5]. They also reported that grade 2 subcuta-
neous toxicity increased three times over 10 years 
from 3.8% to 9.4% with hypofractionation as com-
pared to 30% increase from 5.2% to 6.8% with con-
ventional fractionation [6]. However, in the present 
study, the skin as well as subcutaneous toxicities did 
not deteriorate over time, but chest wall edema re-
gressed with time. Subcutaneous toxicities at 3 and 
5-years were only 2% after postmastectomy radio-
therapy (PMRT). In patients with BCS, subcutane-
ous toxicities at 3 and 5 years were 10% and 11%, 
respectively. The increase in subcutaneous toxicities 
in the Canadian trial may be because of a higher 
total dose of 42.6 Gy. The biological effective dose 
(BED) with this schedule would be 55.88 Gy and 80 
Gy for early and late effects, respectively. The BED 
of 34 Gy/10 fractions/2 weeks would be 45.56 Gy10 
and 72.53 Gy3 for early and late effects, respectively, 
in the case of PMRT. In the case of BCS with ad-
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Figure 5. Brachial plexus Dmean and Dmax (dose along Y-axis and patients along X-axis)
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ditional boost of 10 Gy/5 fractions/1 week to the 
tumor bed, the BED would be 57.56 Gy and 89.2 
Gy, respectively. With hypofractionation, a small 
increase in the total dose can lead to significant 
differences in late toxicities. It was also observed in 
the START pilot trial where patients in the 42.9 Gy 
schedule had significantly increased breast indura-
tion; (40.8% vs. 20.4% vs. 28.6% with 42.9 Gy (3.3 
Gy × 13 fractions); 39 Gy (3 Gy in 13 fractions) 
and conventional fractionation, respectively [7]. 
Similarly, patients treated with 42.9 Gy also had 
significantly higher shoulder stiffness as compared 
to other START trials [10]. Recently, FAST forward 
trial also reported increased normal tissue adverse 
effects with 27 Gy as compared to 26 Gy [11].
Late grade 2 hypopigmentation was observed in 
3 (6%) patients at 5 years (Fig. 7).
Arm and shoulder functions were minimally af-
fected with this schedule. Arm pain was reported 
by only 2 (4%) patients, which is similar to 3% 
reported by Wang et al. [8] There was no deteriora-
tion in the arm and shoulder functions over time 
(Tab. 3). Arm/shoulder function impact rates are 
comparable to the START trials few patients who 
received RNI [10].
Moderate/marked shoulder/arm pain was re-
ported in 8.6–12.1% and 11.4% patients in the 
START A and B trials, respectively. There was no 
RNI in the Canadian study [6].
In the present study, grade ≥ 2 arm edema was 
seen in only 1 (2%) patient (Fig. 8). In the START 
A and B trials, moderate/marked arm edema was re-
ported in 3.3–4.8% and 3.5% patients, respectively. 
In another study, RNI with hypofractionation was 
not reported to add to arm edema [9]. In the cur-
rent study, grade 2 shoulder stiffness was observed 
in only 2 (4%) patients. Moderate/marked shoul-
der stiffness was reported in 3.4–6.9% and 5.6% 
patients in the START A and B trials, respectively 
[10]. Our results are also comparable to the study 
by Wang et al. where they reported lymphedema in 
19% patients [8]. So, there was no detrimental effect 
of this 2-week schedule on arm/shoulder functions. 
There was no brachial plexopathy with this sched-
ule as doses received were well within its toler-
ance limit. However, 1 patient in the START A trial 
treated with 41.6 Gy in 13 fractions was reported to 
have brachial plexopathy [10]. Based on the above 
studies, it appears that a dose of 34 Gy to 40 Gy 
delivered in 10 to 15 fractions may be safe for RNI.
5 years may be too short to report cardiac com-
plications, but there were no cardiac or pulmo-
nary toxicities with this schedule. It may be because 
the doses to the OARs were far lower than those 
reported with conventional fractionation. Only 
mean dose to the heart may not be relevant as it 
is quite low as compared to the dose to the distal 
LAD, which may be responsible for coronary events 
(Fig. 6). So these patients need to be monitored for 
cardiac toxicity in the coming years although hypo-
fractionation may be gentler to the heart because of 
low total nominal dose. Doses to the lung were also, 
within acceptable limits, so we did not encounter 
any pulmonary toxicity (Fig. 4). Recently, we pub-
lished our long-term results of 3-week hypofrac-
tionation; moderate to marked arm pain, shoulder 
stiffness, late cardiac and pulmonary toxicities were 
observed in 254 (14.3%), 219 (12.3%), 29 (1.6%) 
and 23 (1.3%) patients, respectively [12].
So far, the local control with this schedule has 
been 100%. Seven (14%) patients have died, 5 
(10%) because of metastatic disease and 2 (4%) 
because of infection. One patient died because of 
contra-lateral arm sepsis and another from lung 
Figure 8. Late grade 2 arm edema (left)Figure 7. Late grade 2 hypopigmentation
Budhi Singh Yadav et al. Breast cancer hypofractionated radiotherapy
511https://journals.viamedica.pl/rpor
infection. Since all dead patients were included for 
5-year OS calculation, it was 88% as compared to 
90% DFS. These survival outcomes are also com-
parable to those reported in the randomised trials 
[3–8]. Wang et al. also reported 84% OS at 5 years 
in the hypofractionated radiotherapy group in their 
study of high risk patients [8].
Limitations of the study are the small cohorts of 
patients treated with a 2D technique, which may 
be of less relevance to institutes using 3D plan-
ning and treatment. There were no patients in this 
study with skin-sparing mastectomy or immediate 
reconstruction. Considering the safety and efficacy 
of this schedule, it is worth reporting it. Such hy-
pofractionation schedule may help the radiation 
centers worldwide to reduce waiting time for ra-
diotherapy, particularly in low-income countries 
where resources are limited. This schedule would 
also be of relevance in pandemic like covid-19 as it 
is economic, less time consuming, simple to execute 
and possible in any center in the world. It will also 
of economic importance to patients as they can 
complete their treatment fast and cheaper. Based on 
these encouraging outcomes, we have started a ran-
domized trial to compare a 2-week with 3-week ad-
juvant loco-regional radiotherapy in patients with 
breast cancer for which enrollment will be com-
pleted by August 2020 (NCT04075058).
conclusion
Hypofractionated radiotherapy in 2 weeks with 
this 2D technique in patients with breast cancer 
was associated with minimal late toxicity, good cos-
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